140 related articles for article (PubMed ID: 37899576)
1. Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
Sozer Karadagli S; Gursoy P
J Oncol Pharm Pract; 2024 Mar; 30(2):404-407. PubMed ID: 37899576
[TBL] [Abstract][Full Text] [Related]
2. Ribociclib-induced hepatotoxicity.
Er MM; Araz M; Hendem E; Eryılmaz MK; Artaç M
J Oncol Pharm Pract; 2023 Jul; 29(5):1275-1277. PubMed ID: 36762416
[TBL] [Abstract][Full Text] [Related]
3. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
Farhat F; Tarabaih M; Kanj A; Aoun M; Kattan J; Assi T; Awada A
Anticancer Drugs; 2020 Jan; 31(1):85-89. PubMed ID: 31609762
[TBL] [Abstract][Full Text] [Related]
6. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
8. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
9. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
Slamon DJ; Neven P; Chia S; Fasching PA; De Laurentiis M; Im SA; Petrakova K; Bianchi GV; Esteva FJ; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Pivot X; Vidam G; Wang Y; Rodriguez Lorenc K; Miller M; Taran T; Jerusalem G
J Clin Oncol; 2018 Aug; 36(24):2465-2472. PubMed ID: 29860922
[TBL] [Abstract][Full Text] [Related]
10. Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
García-Trevijano Cabetas M; Lucena Martínez P; Jiménez Nácher I; Díaz Almirón M; Zamora Auñón P; Herrero Ambrosio A
Int J Clin Pharm; 2021 Aug; 43(4):893-899. PubMed ID: 33170404
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Yıldırım HÇ; Kutlu Y; Mutlu E; Aykan MB; Korkmaz M; Yalçın S; Şakalar T; Celayir ÖM; Kayıkçıoğlu E; Aslan F; Hafızoğlu E; Altıntaş YE; Keskinkılıç M; Chalabiyev E; Çelebi A; Dursun B; Kapar C; Özen M; Acar Ö; Dülgar Ö; Kut E; Biter S; Kus F; Almuradova E; Erdoğan AP; Saray S; Güven DC; Şimşek ET; Üskent N; Kemal Y; Çakar B; Açıkgöz Ö; Kılıçkap S; Aksoy S
Int J Clin Oncol; 2024 Mar; 29(3):258-265. PubMed ID: 38310597
[TBL] [Abstract][Full Text] [Related]
12. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
13. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
14. Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs.
Giuliani J; Bonetti A
Clin Breast Cancer; 2019 Aug; 19(4):e519-e521. PubMed ID: 30858036
[TBL] [Abstract][Full Text] [Related]
15. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival.
Slamon DJ; Neven P; Chia S; Jerusalem G; De Laurentiis M; Im S; Petrakova K; Valeria Bianchi G; Martín M; Nusch A; Sonke GS; De la Cruz-Merino L; Beck JT; Ji Y; Wang C; Deore U; Chakravartty A; Zarate JP; Taran T; Fasching PA
Ann Oncol; 2021 Aug; 32(8):1015-1024. PubMed ID: 34102253
[TBL] [Abstract][Full Text] [Related]
16. Budget impact of including ribociclib in combination with letrozole on US payer formulary: first-line treatment of post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Mistry R; Suri G; Young K; Hettle R; May JR; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya D; Bhattacharyya S; Mishra D; Dalal AA
Curr Med Res Opin; 2018 Dec; 34(12):2143-2150. PubMed ID: 30032697
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
Bøttcher TM; Cold S; Jensen AB
Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching PA; Decker T; Hartkopf A; Nusch A; Heinrich BJ; Kurbacher C; Fuchs R; Tesch H; Krabisch P; Huober J; Kuemmel S; Brucker S; Janni W; Schneeweiss A; Schuler M; Fehm T; Lüftner D; Quiering C; Voges C; Kreuzeder J; Reinisch M
Eur J Cancer; 2024 Feb; 198():113480. PubMed ID: 38154393
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Verma S; O'Shaughnessy J; Burris HA; Campone M; Alba E; Chandiwana D; Dalal AA; Sutradhar S; Monaco M; Janni W
Breast Cancer Res Treat; 2018 Aug; 170(3):535-545. PubMed ID: 29654415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
